Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Abstract Introduction Glucagon-like peptide-1 (GLP-1) has been the focus of considerable
research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being
used for the treatment of type 2 diabetes mellitus, but consideration of benefits and potential …

Purpose The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment
of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-
weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR) …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are commonly used in combination
with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for …